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ABSTRACT | Pterygium pathogenesis has been mainly asso­
ciated with UV light exposure; however, this association remains 
quite controversial. The complete mechanism of pterygium 
also remains to be clarified. Factors such as inflammation, 
viral infection, oxidative stress, DNA methylation, inflammatory 
mediators, extracellular matrix modulators, apoptotic and 
oncogenic proteins, loss of heterozygosity, microsatellite 
instability, lymphangiogenesis, epithelial­mesenchymal cell 
transition, and alterations in cholesterol metabolism have 
been identified as causes. Several studies aimed to clarify the 
molecular mechanisms underlying the growth and proliferation 
of pterygium. Understanding its molecular basis provides new 
potential therapeutic targets for its prevention and treatment. 
A comprehensive search of the databases, namely, MedLine, 
EMBASE, and LILACS, was conducted with the following key 
words: pterygium, epidemiology, pathogenesis, biomarkers, 
and review. This review describes the epidemiology, clinical 
presentation, and current investigation of biological mediators 
involved in pterygium development. 
Keywords: Pterygium/epidemiology; pathogenesis; Biomarkers; 
Review
RESUMO | A patogênese do pterígio tem sido relacionada, prin­
cipalmente, à exposição à luz ultravioleta, mas esta asso ciação 
permanece bastante controversa. O mecanismo completo do 
pte rígio também permanece por esclarecer. Fatores como 
inflamação, infecção viral, estresse oxidativo, metilação do DNA, 
mediadores inflamatórios, moduladores de matriz extracelular, 
proteínas apoptóticas e oncogênicas, perda de heterozigose, 
instabilidade de microssatélites, linfangiogênese, transição celular 
epitelial­mesenquimal e alterações no metabolismo do coles­
terol tem sido identificados como causas. Diversos estudos 
visam esclarecer os mecanismos moleculares subjacentes ao 
crescimento e proliferação do pterígio. Entender sua base mo­
lecular fornece novos alvos terapêuticos potenciais para sua 
prevenção e tratamento. Uma busca abrangente nas bases de 
dados, a saber, MedLine, EMBASE e LILACS, foi realizada com 
as seguintes palavras­chave: pterígio; epidemiologia; patogênese; 
biomarcadores e revisão. Esta revisão descreve a epidemiologia, 
apresentação clínica e a atual investigação de mediadores bio­
lógicos envolvidos no desenvolvimento do pterígio.
Descritores: Pterígio/epidemiologia; patogênese; Biomarca­
dores; Revisão
INTRODUCTION
Pterygium is a nonneoplastic elastotic degeneration 
of subepithelial growth, originating from the bulbar con­
junctiva that extends to the corneal surface, and even 
reached the visual axis in some cases. It is a common 
ocular surface disorder, especially in geographical areas 
near the equator. The exact cause of pterygium remains 
unclear; however, some risk factors are identified as 
causes, with long­term ultraviolet radiation exposure as 
the most important(1,2). Although pterygium is generally 
regarded as a benign and cosmetic problem, it may result 
in significant visual morbidity or even potential blindness in 
severe cases if not properly treated(3). It usually occurs 
in the nasal area, but can develop temporally or in both 
directions and may even occur bilaterally. Pterygium 
surgery is generally considered when symptoms do not 
respond to conservative treatment, when it induces visual 
disturbances, disability, or for cosmetic purposes(4,5).
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With regard to the mechanisms, genetic factors were 
suggested in some studies, noting that some genes asso­
ciated with DNA repair play a crucial role in pterygium 
development. However, studies on genetic variant 
contributions are limited in sample size and should be 
cautiously interpreted. Chronic irritation with actinic 
damage is likely responsible for the typical fibrovascular 
reaction of pterygium(6). Growth factors, cytokines, and 
matrix metalloproteinase are involved in the pathoge­
nesis of pterygium and, along with UV exposure, may 
trigger the proinflammatory aspects(7).
This review describes the epidemiology, clinical pre­
sentation, and investigation of biological modulators 
found in recent literatures. Therefore, the following 
keywords were searched: pterygium, epidemiology, an­
giogenesis, proliferation, inflammation, gene, protein, 
pathogenesis, and tight junction proteins.
Epidemiology 
The prevalence of pterygium has been investigated in 
several population­based studies. Rates widely vary de­
pending on the studied population, ranging from 2.8% to 
38.7%, as recent studies in South Korea and China found 
prevalences of 8.8%(8) and 9.84%(9), in contrast to 16% 
in Arizona (USA)(10) and 38.7% in Northwest Ethiopia(11).
In Brazil, no population data were conducted on 
pterygium prevalence throughout the country, and only 
a few studies investigated this subject even for specific 
regions. A survey in riverside communities at the Soli­
moes and Japura rivers, in Amazonas, showed that its 
prevalence in the general population was 21.2%(12). Ano­
ther survey, still in the Brazilian Amazon, reported that 
up to 36.6% prevalence of pterygium was observed in 
the indigenous population(13). In the southeast region, a 
study in Botucatu City revealed a prevalence of 8.12%(14).
A large­scale survey on the rate of pterygium and 
other ocular diseases has not been conducted yet. A 
meta­analysis published in 2013, covering a total of 20 
studies involving 12 countries with 900,545 samples, 
showed a combined pterygium prevalence rate of 10.2% 
(95% confidence interval [CI]: 6.3% to 16.1%), in the 
general population(15). Table 1 summarizes the epidemio­
logical information.
Pterygium more frequently occurs in young adults, 
rarely before aged 15 years. It is believed to have some 
inherited patterns; however, several risk factors have 
been reported, such as dust exposure, heat, inflamma­
tion, and eye surface infection, rural residency, advan­
ced age, low educational levels, and outdoor activity(16). 
The prevalence of pterygium has been described as 
higher in males(16); however, other studies have shown 
that both genders have the same proportions(17) or even 
predominantly occurred in women(18). Its relationship with 
smoking was also investigated, but remains inconclusive(15).
Table 1. Epidemiological studies 
Country Study Prevalence Latitude Gender %
Brazil (Amazon) Ribeiro et al., 2011(12) 21.2% 03º 06’ S Male 57.8
Paula et al., 2006(13) 36.6% Female 42.2
Male 15.7
Female 20.5
Brazil (Southeast) Shiratori et al., 2010(14) 8.12% 22º 53’ S Male 10.4
Female 6.5
South Korea Pyo et al., 2016(8) 8.8% 37° 33’ N Male 3.1
Rim et al., 2017(16) 1.9%­3.8% Female 2.5
Male 0.18
Female 0.24
Northwest ethiopia Anbesse et al., 2017(11) 38.7% 12º 31`N Male 2.20
Female 1.0
China Song et al., 2017(9) 9.84% 35° 00’ N Male 10.26
Female 9.46
Nepal Shrestha & Shrestha, 2014(18) 12.4%­65.8% 27º 42`N Male 8.8%­38.5
Female 14.4%­40.7
USA (Arizona) West S & Muñoz B, 2009(10) 16% 34° 30’ N Male 23.7
Female 11.5
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Clinical presentation
Pterygium is a conjunctival fibrovascular tissue that 
extends to the cornea and can lead to irritating symp­
toms, visual disturbance, recurrent inflammation, and 
aesthetic alterations in the ocular surface. Its diagnosis 
is confirmed with slit­lamp examination, in which the 
pterygium can be classified as grade 1, when the fibro­
vascular tissue reaches the limbus; grade 2, when it co­
vers the cornea in approximately 2 mm; grade 3, when it 
reaches the pupil margin; and grade 4, when it exceeds 
the pupil (Figure 1). As regards its morphological featu­
res, pterygium can be classified as involutive or atrophic 
when it allows visualization of structures immediately 
below the lesion and as inflamed once the fibrovascular 
tissue is fleshy and prevents visualization of the structures 
below(19,20). Recently, a functional classification using the 
corneal topographic data based on corneal higher­order 
irregularity was proposed by Miyata et al. to objectively 
evaluate pterygium severity. Hence, pterygium was gra­
ded based on corneal irregularity within the three zones: 
1.0, 3.0, and 5.0 mm diameters. Thus, increased corneal 
irregularity within a 1.0­mm diameter was considered to 
highly result in the risk for visual function impact, and 
increased corneal irregularity within a 5.0­mm diame­
ter was considered as mild severity with visual function 
influences(21).
Visual impairment induced by pterygium growth 
occurs due to induced astigmatism and opacification 
in the visual axis, requiring surgical treatment, as well 
as recurrent inflammation that does not improve with 
topical treatment(20).
Its surgical procedure consists of dissecting the head 
of the pterygium from the cornea and resection of the 
conjunctiva and Tenon’s capsule. Several surgical techni­
ques have been used, with excision of the pterygium 
followed by autologous conjunctival grafts as the most 
common, showing lower recurrence rates. Recurrence 
after a surgical treatment can be identified by the growth 
of conjunctival vessels toward the limbal edge inducing 
fibrous tissue growth into the cornea and representing 
poor outcomes(22). However, clinical features such as ex­
tensive size, inflammation, and recurrent lesions remain 
challenges during the surgical treatment(23,24).
Pathogenesis
UV radiation exposure 
UV radiation from the sunlight is divided into three 
categories:
1. UVA (wavelength, 320­400 nm) has the longest wave­
length and maximum penetration power; thus it is not 
attenuated by the ozone layer. Is an important inducer 
of pigmentation and contributes to premature skin 
aging, immunosuppression, and carcinogenesis(25). 
Figure 2. UV-related mechanism in pterygium development.
Figure 1. Pterygium classification.
Figure 3. Possible biomarkers related to pterygium development.
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2. UVB (wavelength, 280­320 nm) is absorbed by the 
ozone layer and comprises approximately 1%­10% of 
the total UV radiation that reaches the Earth’s surface. 
It is responsible for various biological events, including 
sunburn, immunosuppression, and carcinogenesis(25). 
3. UVC (wavelength, 200­280 nm) has the highest energy 
among the three UV rays and possesses strong muta­
genic properties. It is almost completely absorbed by 
the ozone layer, thereby imposing negligible effects 
to human eyes(26). 
UVB light exposure has been attributed as a major 
cause of pterygium. This kind of radiation can poten­
tially harm and alter cells and tissues through direct 
phototoxic effects on the cellular DNA and generation 
of reactive oxygen species, which damage the cellular 
DNA. Wavelengths below 300 nm have been known as 
the most biologically active forms and are absorbed by 
the cornea. Exposure to UVB radiation causes oxidative 
stress, which may lead to upregulation of many potential 
mediators of pterygium growth(27­29) as shown in figure 2.
Viral infections
The polymerase chain reaction technique allowed 
examination of the alleged involvement of viral infec­
tions in the process of pterygium pathogenesis. Some 
reports demonstrated the presence of herpes simplex 
virus and human papilloma virus (HPV) in pterygium 
samples(30,31). Viruses encode proteins that inactivate 
p53, leading to chromosomal instability and increasing 
the likelihood of cell progression to malignancy. HPV is 
most frequently found in the pterygium, with variable 
pre valence rates(32). Its involvement as a cofactor in 
the pterygium pathogenesis is suggested, but remains 
controversial. If indeed HPV is involved in pterygium pa­
thogenesis or recurrence, anti­viral medications or vac­
cination may be new options in pterygium therapy(30,33).
Molecular mechanisms
Many studies have proposed possible mechanisms 
of pterygium development, including oxidative stress, 
extracellular matrix modulators, apoptotic and onco­
genic proteins, loss of heterozygosis, DNA methylation, 
inflammatory mediators, lymphangiogenesis, transition 
from mesenchymal epithelial cells, and cholesterol me­
tabolism alterations. These studies show evidences that 
several molecules, such as matrix metalloproteinases 
(MMPs), growth factors, and interleukins (ILs), are re­
lated to proliferation, inflammation, angiogenesis, and 
fibrosis, as shown in figure 3 and detailed below(34­36). 
Tumor suppressor genes 
Tumor suppressor genes prevent cells from conver­
ting into cancer cells and regulate cell growth along 
with proto­oncogenes(37). One of the tumor suppressor 
genes that have been extensively studied is p53. A 
survey(38) showed that >20% of all pterygium samples 
were positive for p53 expression. Another immunohis­
tochemical study(37) evaluated 13 pterygium samples and 
2 normal conjunctiva samples, which showed that 54% 
of pterygium were positive for p53 aberrant expression, 
whereas no pathological staining was observed in the 
normal conjunctiva. Therefore, the aberrant expression 
of p53 is suggested to promote cell proliferation and 
slow down apoptosis, thereby accelerating the deve­
lopment of pterygium; besides, the possible growth of 
limbal tumors is also suggested to be caused by cellular 
DNA damage that causes mutations in other genes(39). In 
addition to p53, other tumor suppressor genes, such as 
p63, p16, and p27, were possibly involved in the develop­
ment of pterygium. P63 is more expressed in the basal 
and parabasal layers in primary pterygium and in the 
total thickness of the epithelium in recurrent pterygium. 
Increased expression of p16 protein was also observed 
in pterygium. Both p63 and p16 appeared to be rarely ex­
pressed in the normal conjunctiva(40). P27 gene showed low 
nuclear immuno reactivity in pterygium tissues, differing 
from other tumor suppressor genes(41). 
Apoptosis-related proteins 
Survivin is a protein encoded by the BIRC5 gene in 
humans; it is a member of the apoptosis inhibitory gene 
family and is expressed in the pterygium epithelium(42). 
The molecular mechanisms of survivin regulation are 
still not well understood; however, survivin regulation 
seems to be associated with the p53 protein. Oxidative 
stress has been demonstrated to be caused by the acti­
vation of survivin leading to pterygium growth(43). In 
addition, survivin has been found to be highly expressed 
in all pterygium tissues, but not in the normal human 
conjunctiva. Survivin was found to be closely related 
with COX­2 in primary pterygium, suggesting an antia­
poptotic mechanism(44).
Bcl-2 is the founding member of the Bcl-2 family 
of apoptosis regulatory proteins, which can induce or 
inhibit apoptosis. It is encoded by the Bcl-2 gene in 
humans(45,46). Bcl-2 expression was noted in the basal 
epithelial layer of all pterygium epithelial cells, whereas 
the normal conjunctiva showed no evidence of the pro­
Mechanisms and biomarker candidates in pterygium development
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tein(39). Decreased miR­122 expression in the pterygium 
can result in cell apoptosis abnormalities due to its 
regulation of Bcl-w expression, also a gene of the Bcl-2 
family, anti­apoptotic, and subsequently contribute to 
the development of pterygium(47).
Rapamycin complex 1 (mTORC1) is a central regu­
lator of cell growth, proliferation, protein synthesis, 
autophagy, and transcription. The role of mTORC1 is to 
activate the protein translation. mTOR signaling is highly 
activated; therefore, aberrant apoptosis and cell prolife­
ration were observed in pterygium samples. Activation 
of mTORC1 has been shown to inhibit apoptosis in 
pterygium by regulating Beclin-1­dependent autophagy 
by targeting Bcl-2. mTORC1 also negatively regulates the 
fibroblast growth factor receptor 3 (FGFR3) through the 
inhibition of p73, thereby stimulating cell proliferation 
in pterygium. This demonstrates that mTORC1 signaling 
is highly activated in pterygium and provides new pa­
thways on its pathogenesis and progression(48).
Cell adhesion molecules 
Cell adhesion molecules play an important role in 
various physiological and pathological phenomena. 
These proteins are located on the cell surface and are 
intrinsically involved in cell binding and other extracellu­
lar matrix related to cell adhesion, including selectin, 
and integrin(49). The expression of intercellular adhesion 
molecule­1 (ICAM­1) is found to be present in pterygium 
and absent in the epithelium of a normal conjunctiva(50). 
E­cadherin and beta­catenin have also been suggested to 
be concentrated in the pterygium tissue and are possibly 
involved in the epithelial proliferation and adhesion(51).
Proliferation-related proteins
Proliferation­related proteins such as Ki­67, cyclin D1, 
and nuclear proliferation antigen play a key role in the 
cell cycle. Ki­67 is an important marker of cell prolife­
ration. An abnormal expression of ki­67 was found in 
pterygium samples when compared to a normal conjunc­
tiva(52). Proliferating cell nuclear antigen (PCNA) is a nuclear 
nonhistone protein necessary for DNA synthesis, and 
its expression may be used as a marker of cell prolifera­
tion. The expression of PCNA was significantly higher in 
pterygium than that in a normal conjunctiva(53). Cyclin 
D1 is a well­known cell cycle control gene that pro­
motes cell cycle progression. A study found that PCNA 
and cyclin D1 were overexpressed in the limbal part 
of pterygium epithelial cells as compared with normal 
conjunctiva samples, which might lead to hyperprolife­
ration of epithelial cells(54). Cyclin D1 protein expression 
in fleshy pterygium was found to be significantly higher 
than that in the atrophic ones. Another study indicated 
that β­catenin expressed in the nuclei/cytoplasm could 
increase cyclin D1 protein expression, which favors the 
proliferation of pterygium cells(55).
Heat shock proteins 
Heat shock proteins (HSP) are a protein family produ­
ced by cells in response to exposure to stressful condi­
tions. They were first described in relation to heat shock, 
but are recently known to be expressed during other 
stresses, including exposure to cold temperatures, UV 
light, and during wound healing or tissue remodeling(52). 
The expression of HSPs, i.e., Hsp27, Hsp70, and Hsp90, 
and hypoxia­inducible factor­1α (HIF­1α) were increa­
sed in pterygium. The expression of Hsp27 was detec­
ted in the epithelial, endothelial, and vascular smooth 
muscle cells in pterygium, but only in the epithelium in 
normal conjunctiva(56). Changes in HIF­1α and HSP le­
vels in pterygium are believed to represent an adaptive 
process for cell survival under stressful conditions(57).
Tight junction proteins 
Tight junction proteins represent a form of cell­to­cell 
adhesion in the epithelial or endothelial cell layers, 
forming continuous seals around the cells and also ser­
ving as a physical barrier to prevent solutes and water 
from passing freely through the paracellular space. 
Claudin family proteins are an important part of this 
functional and structural barrier and dysregulation on 
its expression may result in various diseases including 
cancer(58). In normal cornea and conjunctiva, claudin­1 
and claudin­4 positivity were demonstrated immunohis­
tochemically(59).
Claudins are indispensable proteins for the forma­
tion and maintenance of tight junctions. A strong immu­
nohistochemical expression of claudin­1 was found in 
epithelium conjunctiva samples, whereas its expression 
in the pterygium samples was low. The significant decrease 
in claudin­1 expression in the pterygium compared to 
the normal conjunctiva seems to be involved in the pa­
thogenesis of pterygium(60).
Extracellular matrix proteins 
The extracellular matrix (ECM) is a collection of ex­
tracellular molecules secreted by support cells that 
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provide structural and biochemical support to the sur­
rounding cells(61).
The aberrant expression of extracellular matrix 
proteins is believed to may be directly associated with 
the proliferative growth of pterygium, because it is a 
fi brovascular tissue characterized by an excessive depo­
sition of extracellular matrix and vascular growth. The 
extracellular matrix proteins contain keratin, elastin, 
collagen, and fibrin, among others. K8, K16, K14, and AE3 
have been known to be present throughout the thickness 
in the pterygium epithelium but are absent in the nor­
mal conjunctiva(62). In fact, pterygium samples showed 
a higher mRNA level and tropoelastin expression than 
the conjunctival tissue. Type II collagen expression was 
positive only in pterygium, whereas collagen types I, III, 
and IV were detected in both the pterygium and normal 
conjunctiva(63).
Matrix metalloproteinases and tissue  
inhibitors of metalloproteinases 
Matrix metalloproteinases (MMPs), also known as 
ma trixins, hydrolyze components of the extracellular 
matrix. These proteinases play a central role in several 
biological processes, such as embryogenesis, normal 
tissue remodeling, wound healing, and angiogenesis, 
and in diseases such as atheroma, arthritis, cancer, and 
tissue ulceration(64). MMPs are a multigene family of >25 
secreted and cell surface enzymes that process or de­
grade various extracellular matrices(65), which can be di ­
vided into five subgroups based on substrate preference: 
collagenases (MMP­1, MMP­8, MMP­13), gelatinases 
(MMP­2, MMP­9), stromelysins (MMP­3, MMP­10), 
mem brane­associated MMPs (MT1­MMP, MT2­MMP), 
and others (e.g., MMP­12, MMP­19, MMP­20). Tissue 
inhibitors of metalloproteinases (TIMPs) bind to and 
prevent the activities of most MMPs. The relationship 
between pterygium and these two groups of proteins in 
the pathogenesis of pterygium has been studied(39).
MMP­1, MMP­2, MMP­3, TIMP­1, and TIMP­3 were 
detected in greater amounts in pterygium tissues, epithelial 
cells, and fibroblasts as compared to normal conjunc­
tiva(66,67). MMP­3 was positively regulated and located 
in the pterygium epithelium, which may help explain 
the various pterygium phenotypes(68). A study showed that 
cyclosporin A can reduce MMP­3 and MMP­13 expres­
sions in the pterygium fibroblast culture(69).
MMP and TIMP expressions vary at the different 
stages of pterygium. The balance break between MMPs 
and TIMPs may be considered to be responsible for the 
progression or recurrence of pterygium(39).
ILs
ILs are a group of cytokines, secreted proteins, and 
signal molecules first seen to be expressed by the white 
blood cells (leukocytes). These cells play vital roles in the 
inflammation process; thus, ILs can be closely related to 
pterygium(66). 
The expression of IL­1α, IL­1β RA, and IL­1β precur­
sor proteins in primary pterygium and normal conjunc­
tival epithelium were detected via immunofluorescence. 
Enhanced levels of IL­1 family proteins were present in 
pterygium only. Likewise, IL­1α was found to be highly 
expressed not only in primary but also in recurrent 
pterygium(67).
IL­6 and IL­8 were strongly expressed in the pterygium 
epithelium as compared to the normal cornea, conjunc­
tiva, and limbus. In addition, IL­6 and IL­8 proteins were 
significantly elevated in pterygium treated with UVB, 
suggesting that UVB could induce the secretion of these 
two ILs(70). IL­8 can also induce corneal vascularization 
directly(71). IL­10 had also been reported to be expressed 
more in pterygium than that in the normal conjunctiva. 
Recently, IL­17 was found to be upregulated in the ocular 
surface in inflammatory pathologies, such as pterygium(72).
Growth factors 
A growth factor is a natural substance capable of sti­
mulating cellular growth, proliferation, healing, and cellu­
lar differentiation. They are important in the regula tion 
of various cellular processes, such as mitosis(73). 
Numerous growth factors are thought to have a role 
in pterygium pathogenesis, such as the vascular endo­
thelial growth factor (VEGF), transforming growth fac­
tor­beta (TGF­β), basic fibroblast growth factor (bFGF), 
insulin­like growth factor, nervous growth factor, and 
connective tissue growth factor (CTGF)(7). The VEGF fa­
mily has been extensively investigated in ophthalmology, 
because of its role in pathological angiogenesis and in 
increasing the vascular permeability in ocular diseases, 
such as pterygium and retinal diseases(74). 
Increased expression of VEGF leads to angiogenesis 
and lymphangiogenesis, which may influence the normal 
metabolism of the connective cells and promote vascu­
lar growth. When compared to the normal conjunctiva, 
pterygium showed higher VEGF levels(75,76). TGF­β re­
gulates various processes common to tissue repair and 
Mechanisms and biomarker candidates in pterygium development
534 Arq Bras Oftalmol. 2019;82(6):528-36
disease, including fibroblast proliferation, angiogenesis, 
synthesis, and degradation of extracellular matrix pro­
teins(77). TGF­β1 and TGF­β2 were found to be positively 
regulated, whereas transforming growth factor­beta 
receptor 1,2 (TGFR­β1, β2) was negatively regulated in 
pterygium(78,79).
Anti­VEGF drugs such as ranibizumab and bevacizumab 
have been widely used for the treatment and control of 
ocular diseases associated with vascular proliferation(80). 
Although some studies suggest the use of anti­VEGF as an 
adjuvant therapy for surgery, studies conducted to charac­
terize its use for the treatment of pterygium are lacking(81). 
Understanding the etiopathogenesis and most rele­
vant factors involved in pterygium may allow advances on 
strategies to prevent its onset and progression, which may 
even prevent surgical procedures in the future. Although 
various studies have already been conducted, important 
genes and proteins have probably not yet been disco­
vered. In this sense, performing additional research to 
better understand the etiopathogenic mechanisms and, 
thus, promote more targeted and effective treatment 
options, especially in recurrent cases, may be interesting.
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